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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with three different human
malignancies including Kaposi’s sarcoma (KS), primary effusion lymphoma and multicentric
Castleman’s disease. The KS lesion is of endothelial cell in origin and is highly dependent on
autocrine and paracrine factors for survival and growth. In this study, we demonstrate that KSHV
infection of endothelial cells induces the activation of the pro-survival PI3K/Akt/mTOR pathway.
KSHV infection of endothelial cells augmented cell survival in the presence of apoptotic inducers,
including etoposide and staurosporine, and under conditions of serum deprivation. We found that
KSHV infection of endothelial cells also increased the ability of these cells to form an in vitro tubular
network under conditions of stress and growth factor deprivation. Finally, we show that the NF-κB
and PI3K pathways are also required for endothelial tubular network formation. Collectively, these
results suggest that KSHV infection of endothelial cells modulates cell signaling pathways and
induces cell survival and angiogenesis, thereby contributing to the pathogenesis induced by KSHV.
Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) is a gammaherpesvirus first
identified from Kaposi’s sarcoma (KS) biopsies (1). Since its discovery, KSHV has been found
in all epidemiological forms of KS, and viral genomic DNA is present in AIDS-associated KS
as well as HIV-negative classic and transplant-associated KS (2). KSHV is also linked to two
lymphoproliferative diseases: primary effusion lymphomas (PELs) and multicentric
Castleman’s disease (MCD)(3,4).
Angiogenesis is the formation of new blood vessels from a pre-existing microvascular network.
Angiogenesis is important for many normal physiological processes such as organ development
and wound healing (5). Many tumors usurp this process and angiogenesis is central for tumor
growth and metastasis.
KS is a highly inflammatory and angiogenic vascular tumor with characteristic spindle cells
that are of endothelial origin (6). The KS lesion has been shown to express high levels of
vascular endothelial growth factor (VEGF) and fibroblast growth factor (bFGF/FGF-2), which
are necessary for the maintenance of the lesion (7). In addition, KS-derived cells were found
to constitutively release matrix metalloproteinase 9 (MMP-9) (8). Recent studies have shown
that KSHV infection of endothelial cells in vitro induces the secretion of angiopoietin 2,
MMP-2 and MMP-9 (9-12). Furthermore, anti-angiogenic therapies are currently being used
for treatment of KS (13).
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The angiogenic potential of several genes of KSHV has also been investigated. KSHV G
protein-coupled receptor (vGPCR) is a homolog of human IL-8 receptor, and can induce
constitutive, ligand-independent signaling activity. Signaling by vGPCR results in elaboration
of many mitogenic and angiogenic cytokines that are vital to KSHV biology and KSHV-driven
malignancies. vIL6, a homolog of human IL-6 has also been implicated in the development of
tumorigenesis and angiogenesis (14). Our recent studies have shown that the K1 protein of
KSHV induces the secretion of VEGF, MMP-9, and also enhances angiogenesis and tumor
size in vivo (15).
The PI3K/Akt signaling pathway plays an important role in cell growth and survival. PI3K is
a heterodimer composed of a catalytic subunit (p110) and an adaptor/regulatory subunit (p85),
which are activated by receptor activation. PI3K activation leads to Akt activation and
phosphorylation on residues Threonine 308 and Serine 473 (16,17). Akt is a critical regulator
of PI3K-mediated cell survival, and it phosphorylates and inactivates several pro-apoptotic
proteins including members of the forkhead family of transcription factors (FKHR/FOXO) and
glycogen synthase kinase-3 beta (18,19). Activated Akt also enhances protein synthesis
through increasing the phosphorylation of the mammalian target of rapamycin (mTOR) (20).
As a serine/threonine protein kinase, mTOR has been shown to regulate cell growth,
proliferation, motility, survival, protein synthesis, and gene transcription (21,22). Akt can
activate mTOR in different ways. First, Akt can directly phosphorylate and activate mTOR
(23). Second, it can activate mTOR through phosphorylation and inhibition of tuberous
sclerosis complex 2 (TSC 2), which is a negative regulator of mTOR (24,25). Third, Akt can
modulate mTOR activity through the regulation of cellular ATP levels which leads to the
inactivation of AMP-activated protein kinase (AMPK) and TSC 2 (26).
We have previously shown that the KSHV K1 protein activates the PI3K/Akt/mTOR pathway
in B cells and endothelial cells (15,27). Similarly, KSHV vGPCR has also been found to
upregulate the PI3K/Akt/mTOR pathway (28-30). These studies were performed with
individual KSHV viral genes, and in this manuscript we examined the role of PI3K/Akt/mTOR
activation on endothelial cell survival in the context of the whole virus.
Here, we report that KSHV infection of endothelial cells enhances angiogenesis, activates the
PI3K/Akt/mTOR pathway, and inactivates AMPK. We find that this activation of the PI3K/
Akt cell survival pathway in endothelial cells infected by KSHV confers a survival advantage
and protects infected cells from apoptosis.
Materials and Methods
rKSHV.219 Production
Vero cells containing latent rKSHV.219 (KSHV-Vero) and a recombinant baculovirus KSHV
Orf50 (BacK50) were kindly provided by Dr. Jeffrey Vieira (31). rKSHV.219 expresses green
fluorescent protein (GFP) from the EF-1α promoter, and puromycin resistance gene as a
selectable marker (32). The insect SF9 cells were grown in Grace’s insect media (Gibco)
supplied with 10% fetal bovine serum (FBS) at 28°C in a 5% CO2 incubator. Three days post
BacK50 infection, the baculovirus-containing supernatant was separated from SF9 cells by
centrifugation (3500 rpm for 10 min). KSHV-Vero cells were infected with BacK50 and treated
with 1mM sodium butyrate. At 65-72 hours post infection, media was harvested and cells were
removed by centrifugation (3500 rpm for 10 min). Supernatants were passed through a
0.45μm filter.
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Infection of Endothelial cells
Primary human umbilical vein endothelial cells (HUVEC) from Clonetics were cultured in
sterile endothelial growth medium (EGM-2, Clonetics) with 10% FBS and were maintained
at 37°C in a 5% CO2 environment. Immortalized HUVEC were made by infecting primary
HUVEC with a hTERT-encoding retrovirus that also expressed the hygromycin resistance gene
as previously described (32). rKSHV.219 produced from KSHV-Vero cells was used to infect
immortalized HUVEC in the presence of 0.8mg/ml polybrene. After three days, the cells were
selected in media containing 0.5μg/ml puromycin for about two weeks to select for stable
KSHV-HUVEC.
Serum-Starvation Assay
1×105 primary immortalized HUVEC and KSHV-HUVEC were plated in each well of a 6-
well plate and cultured in EGM-2 with 10% FBS at 37°C. After 24 hours, cells were washed
twice with PBS and cultured in endothelial basic media, EBM-2 (Clonetics) with no serum or
supplements in a 37°C incubator for up to 5 days. The images were taken with a Zeiss Axiovert
200 inverted fluorescence microscope. The number of cells in ten different fields were counted
and averaged after trypan blue staining.
Caspase-3 Activation Assay and PARP-1 Activity Assay
1×106 cells HUVEC and KSHV-HUVEC were seeded in 100mm dishes. After 24 hours, the
cells were washed twice with PBS, and then treated with EBM-2 media containing one of the
following: DMSO vehicle control, 500 ng/ml TNFα (Sigma), 100 μM etoposide (Sigma) or
20nM staurosporine (Sigma) for 24 hours (33,34). The cells were harvested and a Caspase-3
activation assay was performed using the ApoAlert® Caspase-3 Fluorescent Assay kit
(Clontech). A PARP-1 activity assay was also performed using the Universal Colorimetric
PARP Assay kit (Trevigen). In addition, the Caspase-3 inhibitor, Z-VAD-FMK (Sigma), was
used in the Caspase-3 activation and PARP-1 assays. In this case cells were grown in EGM-2
complete media with 10%FBS and treated with one of the following: DMSO vehicle control,
100 μM etoposide, 100 μM etoposide plus 50 μM Z-VAD-FMK (35), 20 nM staurosporine,
or 20 nM staurosporine plus 50 μM Z-VAD-FMK (35) for 24 hours. Caspase-3 and PARP-1
activity was measured in the cells using the ApoAlert® Caspase-3 Fluorescent Assay kit and
the Universal Colorimetric PARP-1 Assay kit, respectively.
Western Blots
HUVEC and KSHV-HUVEC were seeded and grown in EGM-2 media, and after 48 hours,
the cells were washed with ice-cold PBS containing 1 mmol/L Na3VO4 and protease inhibitor
cocktail (Roche, Mannheim, Germany). Cells were lysed in Triton/NP40 lysis buffer. Western
blots were performed with the following antibodies: rabbit phospho-(Tyrosine) p85 PI3K
binding motif antibody (1:2000 dilution), rabbit phospho-Akt (Ser473) antibody (1:1000
dilution), rabbit phospho-mTOR (Ser2448) antibody (1:2000 dilution) and phospho-AMPK
(Thr172) antibody (1:1000 dilution). All of these antibodies were from Cell Signaling
Technology (Beverly, MA).
Tubule Formation Assays
A KSHV-negative lymphoma cell line, BJAB, and the body-cavity-based lymphoma cell line
BCBL-1 were grown in RPMI media (Cellgro) with 10% FBS. Cells were washed with PBS
twice, and then incubated in serum-free plain RPMI media for 48 hours at 37°C. The conditional
media from BJAB and BCBL-1 cells was harvested by centrifugation at 3500 rpm for 10 min.
Growth factor-reduced Matrigel (BD Biosciences) was added to the wells of a pre-chilled 24-
well plate (0.25ml per well). The plate was placed in a 37°C incubator for 30 min and the
matrigel was allowed to solidify. To determine whether the cells could form tubules in B cell
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conditioned media, 3×104 immortalized HUVEC and KSHV-HUVEC were resuspended in
either 1ml plain RPMI media or conditioned media from BJAB or BCBL-1 cells, and were
then plated on the solidified matrigel. The plate was incubated in a 37°C incubator for different
time points and images were taken with a Nikon T200 fluorescence microscope. To determine
whether the cells could form tubules in the absence of VEGF and FGF, the cells were
resuspended in VEGF minus EGM-2 media or FGF minus EGM-2 media, plated on the
solidified matrigel and incubated at 37°C for upto four days. For the VEGF antibody
experiments, HUVEC and KSHV-HUVEC were resuspended in EBM-2 media or EBM-2
media containing 20μg/ml VEGF antibody (Sigma) (36). The cells were then seeded on
matrigel and incubated at 37°C incubator for16 hours. Images were taken with a Nikon T200
fluorescence microscope.
For drug treatment experiments, 3×104 immortalized HUVEC and KSHV-HUVEC treated
with EBM-2 media overnight were resuspended in 1ml EGM-2 media containing either 50nM
Rapamycin (mTOR inhibitor, Calbiochem) (37), 150μM Ciglitazone (AMPK activator,
Calbiochem), 2.5μM SU6656 (Src inhibitor, Sigma) (38), 20μM Piceatannol (Syk inhibitor,
Calbiochem) (39), 5μM Bay11-7085 (NF-κB inhibitor, Calbiochem) (40) or 20μM LY294002
(PI3K inhibitor, Calbiochem) (41). The cells were then plated on the solidified matrigel. The
plate was put in a 37°C incubator for 4 hours. The angiogenic index was calculated as the
number of branch points in a field for a particular treatment. Five different fields were counted
for each treatment and the number of branch points was averaged.
Results
KSHV infection of endothelial cells induces activation of the PI3K/Akt/mTOR pathway and
inactivation of AMPK
In order to obtain KSHV infected endothelial cells, HUVEC were infected with a recombinant
KSHV virus containing a green fluorescent protein (GFP) expression cassette and a puromycin
expression cassette (31). After selection with 0.5μg/ml puromycin for several weeks, we
obtained a 100% KSHV-infected stable HUVEC cell line, which is denoted as KSHV-HUVEC.
In order to determine whether the KSHV infected endothelial cells displayed an activated PI3K/
Akt/mTOR pathway, equal micrograms of HUVEC and KSHV-HUVEC cell lysate were
loaded on SDS-PAGE and subjected to western blot analysis with antibodies directed against
components of the PI3K/Akt pathway. KSHV infection of HUVEC resulted in increased
phosphorylation of the p85 sub-unit of PI3K (Fig. 1), indicative of its activation. We also found
that there was increased phosphorylation of Akt on Serine 473, concomitant with its activation
(Fig.1). mTOR, a downstream target of Akt also appeared to be more activated in KSHV-
infected HUVEC compared to uninfected HUVEC, as evidenced by phosphorylation of serine
residue 2448. Interestingly, AMPK, a negative regulator of mTOR, showed decreased
phosphorylation on threonine residue 172 in KSHV-infected HUVEC (Fig. 1), suggesting that
AMPK is less activated in KSHV-infected HUVEC compared to uninfected HUVEC. Thus,
the net effect of KSHV infection of endothelial cells is activation of the PI3K/Akt/mTOR
pathway and inactivation of AMPK (Fig. 1).
KSHV infection augments endothelial cell survival upon serum deprivation
Since we observed that the PI3K/Akt pathway was activated in KSHV-HUVEC and because
this pathway has been associated with cell survival (42,43), we determined whether the KSHV-
infected cells were more resistant to apoptosis induced by serum starvation. We subjected
uninfected HUVEC versus KSHV-infected HUVEC to serum starvation using EBM-2 media
without serum or cytokine supplements for various time-points. Twenty-four hours post-serum
starvation there was no significant difference between the two cell lines, but by 48 hours, some
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of the uninfected HUVEC died and most of the uninfected HUVEC appeared to be undergoing
apoptosis. In contrast, the KSHV-HUVEC appeared healthy (Fig. 2). By 72 hours, more than
60% of the uninfected HUVEC died and had come off the plate. At this time-point, most of
the KSHV-infected HUVEC still appeared healthy and were attached to the dish. At 96 hours
(day 4) there were only a few surviving uninfected HUVEC compared to KSHV-HUVEC. By
120 hours (day 5), almost all of the uninfected HUVEC died. In contrast, about 40% of KSHV-
HUVEC remained alive at day 5 and maintained normal endothelial cell morphology and
behavior (Fig 2). These results have been repeated four times. Our results suggest that KSHV
infection protects endothelial cells under serum starvation conditions.
KSHV infection suppresses etoposide and staurosporine-induced apoptosis
Next, we sort to determine the ability of uninfected versus KSHV-infected HUVEC to
counteract various apoptotic stimuli. HUVEC and KSHV-HUVEC were treated with DMSO
(control), or apoptosis inducers including 500ng/ml TNF-α, 100 μM etoposide or 100 nM
staurosporine for 24 hours. Caspase-3 is a cysteine protease that has been identified as a key
mediator of cell apoptosis and its activation is often used as a hallmark of apoptosis (44,45).
The HUVEC and KSHV-HUVEC cells were then harvested and lysed. Equal micrograms of
cell lysates were used to perform Caspase-3 activation assays using a colorimetric assay that
measures the cleavage of the Caspase-3 peptide substrate, DEVD-7-amino-4-trifluoromethyl
coumarin (DEVD-AFC) resulting in AFC, which could be detected at an emission of 505 nm.
Etoposide inhibits DNA synthesis (46) and staurosporine is a relatively non-selective inhibitor
of several protein kinases including protein kinase C and protein kinase A (47,48). Both of
these drugs have previously been shown to induce cellular apoptosis (33,34). As shown in Fig.
3A, with the treatment of 100 μM etoposide, the activity of Caspase-3 in the uninfected HUVEC
was more than twice that of the KSHV-HUVEC, suggesting that KSHV infection of endothelial
cells confers a protective effect against etoposide-induced apoptosis. Similarly, activation of
Caspase-3 in staurosporine-treated KSHV-HUVEC was lower than that seen in staurosporine-
treated uninfected HUVEC (Fig. 3A). Together these data suggest that KSHV infection inhibits
endothelial cell apoptosis induced by either etoposide or staurosporine.
Interestingly, TNF-α treatment of either HUVEC or KSHV-HUVEC did not seem to induce
much apoptosis in either cell line as measured by Caspase-3 activity (Fig. 3A). This has been
previously reported for TNF-α exposure of HUVEC (49). A20, a TNF-α inducible early
response Zinc finger protein, has been previously shown to downregulate NF-κB signaling in
HUVEC and also inhibit apoptosis of endothelial cells induced by TNF-α (50,51). Thus,
endothelial cells appear to be resistant to the effects of TNF-α.
Further, to determine whether the apoptosis we observed with etoposide and staurosporine was
Caspase-3-dependent, we performed Caspase-3 activity assays with HUVEC and KSHV-
HUVEC in the presence of the Caspase-3 inhibitor, Z-VAD-FMK. As shown in Fig. 3B,
apoptosis induced by both etoposide and staurosporine was Caspase-3 dependent since almost
no apoptosis was induced in either HUVEC or KSHV-HUVEC with etoposide or staurosporine
in the presence of the Caspase-3 inhibitor, Z-VAD-FMK (Fig. 3B).
We also performed poly (ADP-ribose) polymerase (PARP-1) activity assays to measure
apoptosis. PARP-1 catalyzes the NAD-dependent addition of poly ADP-ribose to adjacent
nuclear proteins (52). During apoptosis, PARP-1 is specifically cleaved from its enzymatically
active form to an inactive form, and the cleavage of PARP has been demonstrated to be a
reliable marker for apoptosis in a wide variety of cell types (53-56). We performed a PARP-1
activity assay using lysates from HUVEC or KSHV-HUVEC treated with etoposide or
staurosporine. Higher PARP-1 activity corresponds to lower apoptosis and conversely, lower
PARP-1 activity corresponds to a higher degree of apoptosis. We found that the PARP-1
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activity in HUVEC treated with etoposide or staurosporine was lower than the PARP-1 activity
seen in KSHVHUVEC treated with these same drugs (Fig. 3C). This is consistent with the
Caspase-3 activity data shown in Fig. 3A. Finally, we also performed the PARP-1 activity
assay in the presence of the Caspase-3 inhibitor, Z-VAD-FMK (Fig. 3D). The presence of Z-
VAD-FMK greatly increased PARP-1 activity in the etoposide and staurosporine treated
HUVEC and KSHV-HUVEC. In summary, our data indicates that Caspase-3-mediated
apoptosis by etoposide and staurosporine is much reduced in KSHV-infected HUVEC as
compared to uninfected HUVEC.
KSHV-infected endothelial cells form tubular networks under conditions of cell stress
The tubule formation assay is an in vitro assay for monitoring the formation of capillary-like
tubules by endothelial cells and is used to model and measure cell angiogenesis (57). We used
growth factor-reduced matrigel as the basement matrix to induce endothelial cell tubule
formation under various conditions. Unlike standard matrigel, growth factor-reduced matrigel
contains significantly lower levels of stimulatory cytokines and growth factors which allowed
us to compare infected and uninfected HUVEC without the complications of high levels of
cytokines in the media. HUVEC and KSHV-HUVEC were plated on matrigel and allowed to
form tubule networks. We found that the KSHV-infected HUVEC formed more tubule
structures than uninfected HUVEC within a 24-hour period (Fig. 4A).
KSHV is associated with KS, a tumor of endothelial origin, and primary effusion lymphoma
(PEL), a tumor of B cell origin. We wanted to investigate whether media from KSHV-positive
B cell lymphomas could sustain endothelial tubule formation of KSHV-infected HUVEC.
BJAB is a KSHV-negative B cell lymphoma and BCBL-1 is a KSHV-positive B cell
lymphoma. We cultured the two cell lines in plain media without serum for 48 hours and then
harvested the media for endothelial tubule formation assays, to see whether HUVEC and
KSHV-HUVEC could form tubules in the presence of the conditioned media from these two
B cells. We found that uninfected HUVEC could not form any tubule networks in either plain
media without serum or the conditioned media collected from BJAB cells (Figure 4B and 4C).
In contrast, KSHV-HUVEC formed a branching network of tubules to a significantly greater
extent than uninfected HUVEC in BJAB conditioned media (Figure 4B and 4C). Furthermore,
the conditioned media from the KSHV positive PEL (BCBL-1) amply supported capillary-like
tubule formation of KSHV-HUVEC (Fig. 4B and 4C). The KSHV-HUVEC tubules formed in
the conditioned BCBL-1 media were also more intact compared with KSHV-HUVEC tubules
formed in either plain media without serum, or the conditioned media from BJAB cells. The
uninfected HUVEC did form a couple of tubular structure in the presence of BCBL-1 cells but
to a significantly lesser degree than KSHV-HUVEC. This suggests that KSHV-positive
BCBL-1 cells secret pro-angiogenic cytokines and growth factors that enhance the
angiogenesis associated with endothelial cells, and to a greater degree with KSHV-infected
endothelial cells.
KSHV-infected endothelial cells form tubules in the absence of exogenous VEGF and bFGF
VEGF and bFGF are two important growth factors involved in endothelial cell proliferation
and angiogenesis. Many groups have reported that infection of endothelial cells with KSHV
results in increased production of VEGF (58,59). We have also found that KSHV-HUVEC
secreted more VEGF than uninfected HUVEC (data not shown). We performed tubule
formation assays in the absence of VEGF or FGF to determine if deprivation of these growth
factors affects endothelial cell tubule formation over a four-day time course. We found that at
24 hours after seeding the cells on matrigel, both HUVEC and KSHV-HUVEC formed
networks of tubules in complete EGM-2 media, VEGF-minus EGM-2 media and bFGF-minus
EGM-2 media (Fig 5A). By day 2, some of the tubules formed by HUVEC and KSHV-HUVEC
in complete media were broken, but most of them were maintained very well, and there was
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no significant difference between the two cell lines (Fig 5A). However, in the VEGF-minus
EGM-2 media and the FGF-minus EGM-2 media, there were a significantly greater number
of uninfected HUVEC tubules that were broken. In contrast, more intact tubules could still be
visualized in the KSHV-HUVEC cells incubated in VEGF-minus EGM-2 media or FGF-minus
EGM-2 media (Fig. 5A). By the third day, most of the uninfected HUVEC died and almost all
of the tubules were disintegrated. In contrast, we still found some intact tubular structures in
the KSHV-HUVEC sample (Fig. 5A). Finally, on day 4, almost all of the uninfected HUVEC
were dead but a proportion of the KSHV-HUVEC cells were still expressing GFP and formed
tubules to some extent (Fig. 5A). Thus, KSHV infection of HUVEC confers a survival
advantage and helps maintain the endothelial tubular network under conditions of growth factor
deprivation.
Since we and other have previously reported that KSHV infection of endothelial cells results
in VEGF upregulation, we next determined whether VEGF production by KSHV-HUVEC
contributes to the increased angiogenesis seen with these cells. Hence, we performed the above
tubule assays with HUVEC and KSHV-HUVEC in serum-free EBM-2 media containing a
blocking anti-VEGF antibody (20μg/ml). We found that in the presence of the anti-VEGF
antibody there were hardly any tubules formed by the uninfected KSHV-HUVEC (Fig. 5B).
Although significantly inhibited, the KSHV-infected HUVEC still managed to form a very
small number of tubules in the presence of the VEGF blocking antibody (Fig. 5B), suggesting
that KSHV-HUVEC continuously secrete more VEGF and all of it is not completely blocked
by the antibody.
NF-κB and PI3K pathways are essential for tubule formation by KSHV-HUVEC
We next determined the cellular pathways that are important for KSHV angiogenesis in
vitro. We used a series of drug inhibitors to treat the endothelial cells in our tubule assays to
determine which signaling pathways may play a key role in endothelial cell tubule formation
and angiogenesis. In the presence of DMSO vehicle control, 2.5μM SU6656 (Src inhibitor)
(38), or 20μM Piceatannol (Syk inhibitor) (39), both HUVEC and KSHV-HUVEC formed
tubule networks (Fig 6A), implying that the Src and Syk signal transduction pathways are not
necessary for HUVEC or KSHV-HUVEC angiogenesis in vitro under these conditions.
We also tested the importance of AMPK and mTOR signaling in tubule formation (Fig 6A).
We found that activation of AMPK by 150 μM Ciglitazone or inhibition of mTOR by 50 nM
rapamycin completely disintegrated the HUVEC cells and reduced the number of tubules
formed by the KSHV-HUVEC (Fig. 6A and B). The same was true when we used 1 μM
rapamycin (data not shown).
Interestingly, 5μM Bay11-7085 (NF-κB inhibitor) treatment killed the HUVEC and KSHV-
HUVEC and did not support tubule formation in either cell type (Fig 6A and B). Furthermore,
20μM LY294002 (PI3K inhibitor) treatment resulted in a modest effect on the tubule formation
of uninfected HUVEC, although most of the cells appeared unhealthy. In contrast, most of the
KSHV-HUVEC died and could not form intact tubules with LY294002 treatment (Fig 6A and
B). These data suggest that the KSHV-HUVEC cells are more sensitive to inhibition of the
PI3K signaling pathway than uninfected HUVEC. Thus, the NF-κB, PI3K, mTOR and AMPK
proteins are important for the viability and angiogenic properties of endothelial cells.
Discussion
In order to proliferate in an uncontrolled fashion, many cancer cells not only bypass cell cycle
check-points but also inhibit apoptotic pathways thereby ensuring their survival (see review
by Bocchetta and Carbone (60)). KSHV is associated with three different malignancies in the
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human population. In this report we have evaluated the ability of KSHV to protect endothelial
cells from different apoptotic stimuli.
It is well established that the PI3K/Akt signaling pathway regulates cell proliferation and cell
survival (42). Here we report that KSHV infection of endothelial cells induces activation of
the PI3K and Akt kinases compared to uninfected cells. KSHV infected cells also show a
decreased activation of AMPK and an increase in phosphorylation and activation of mTOR.
Previous studies have shown that two KSHV oncoproteins, vGPCR and K1, activate the PI3K/
Akt/mTOR signaling pathway in B cells and endothelial cells, and immortalize primary
HUVEC (15,27,29,30).
Since activation of the PI3K/Akt pathway has been linked to cell survival events, we
investigated whether the KSHV-infected cells had a cell survival advantage over uninfected
cells under conditions of cell stress. We found that the KSHV-infected HUVEC were protected
from serum starvation for a longer period of time compared to uninfected HUVEC and a
significantly higher proportion of the KSHV-infected cells were alive five days post-serum
starvation compared to uninfected cells. Furthermore, the KSHV-HUVEC were more resistant
to etoposide- and staurosporine-induced cell death compared to uninfected HUVEC as
measured by Caspase-3 and PARP-1 activity assays.
We also evaluated the ability of KSHV-infected cells to mediate angiogenesis under suboptimal
conditions using an in vitro tubule formation assays. In all experiments, KSHV-infected cells
could form more tubules in the absence of serum, or in conditioned spent media from KSHV-
negative BJAB cells and KSHV-positive BCBL-1 cells, than uninfected HUVEC. This is likely
due to the fact that several KSHV viral proteins have been shown to increase VEGF expression
and secretion (29,61) and hence KSHV-infected cells may be less dependent on external growth
factors than uninfected cells. Interestingly, in the presence of conditioned media from BCBL-1
cells (and no exogenous growth factor addition), both uninfected HUVEC and KSHV-infected
HUVEC could form tubules with the latter forming a significantly higher number of tubules.
KSHV-infected PEL have previously been shown to secrete cytokines and growth factors such
as VEGF and IL-6 (14,37,62) in the supernatant that likely facilitates this endothelial tubule
formation.
Additionally, the KSHV-infected HUVEC could also form more tubules than uninfected cells
when either VEGF or bFGF was removed from the endothelial cell media or when a blocking
VEGF antibody was added to the media. Moreover, the KSHV-HUVEC maintained their
tubule structures in the absence of VEGF or bFGF for a longer period of time (upto 4 days)
compared to uninfected cells. It has previously been shown that KS lesions have high-levels
of expression of VEGF and bFGF (9-12,63) and this suggests that VEGF secreted from infected
cells contributes to endothelial cell survival and angiogenesis.
Finally, it appears that the PI3K and NF-kB pathways are critical for KSHV-induced tubule
formation. We performed tubule formation assays in the presence of inhibitors of Syk, Src,
PI3K, mTOR, AMPK, and NF-kB. The Src and Syk inhibitors did not show any effect on the
ability of the KSHV-HUVEC or uninfected HUVEC to form tubules. However, inhibitors of
PI3K (LY294002), NF-kB (Bay11-7085), mTOR (Rapamycin) and AMPK (Ciglitazone)
either inhibited or reduced the ability of KSHV-HUVEC from forming tubules. NF-kB
inhibition completely obliterated the KSHV-HUVEC and uninfected HUVEC from forming
tubules suggesting that this pathway is essential for angiogenesis. Interestingly, the PI3K
inhibitor LY294002 reduced the ability of uninfected HUVEC to form tubules, but the KSHV-
infected HUVEC were much more susceptible to PI3K inhibition suggesting that these cells
are highly dependent on PI3K activation. Weinstein and colleagues originally proposed the
concept of oncogene addition in which cancer cells often rely on the activation of a specific
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signaling pathway. They suggest that inhibition of this specific pathway leads to preferential
death of the cancer cell over a normal cell (64). A similar situation may be occurring in the
KSHV-infected endothelial cells where they are more sensitive to PI3K inhibition than normal
cells. This implies that therapeutic targets that inhibit members of the PI3K signaling pathway
may be beneficial in the clinic against KS. Indeed, sirolimus (Rapamycin) which targets mTOR,
the downstream effector of the PI3K and Akt kinases, has been shown to be efficacious against
KS (37,65). Further, we have recently published that Rapamycin is also effective against PEL
and can inhibit PEL cell growth in vitro and tumor formation in immunocompromised mice
(37,65). The data presented here demonstrates that rapamycin inhibition of mTOR reduces the
number of tubules formed by the KSHV infected HUVEC by fifty percent. Further, inhibition
of the upstream kinase PI3K using LY294002, completely inhibited KSHV-HUVEC tubule
formation. This suggests that inhibitors of the PI3K/Akt/mTOR pathway may prove efficacious
against a broad spectrum of KSHV-associated cancers, including PEL and KS.
Taken together, our results provide compelling evidence that KSHV infection activates the
PI3K/Akt/mTOR signaling pathway in endothelial cells and confers a cell survival and
angiogenic advantage to these cells.
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Figure 1. KSHV infection induces activation of the PI3K/Akt/mTOR pathway
HUVEC and KSHV-HUVEC were harvested 48 hours post-seeding, and equal micrograms of
cell lysates were subjected to SDS-PAGE. The gel was transferred to nitrocellulose and western
blots were performed with the indicated antibodies. KSHV infection of endothelial cells
increased phosphorylation of the p85 sub-unit of PI3K, phosphorylation of Akt, and mTOR.
We also found that KSHV-HUVEC displayed a decrease in the phosphorylation of AMPK.
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Figure 2. KSHV infection confers endothelial cell survival upon serum deprivation
HUVEC and KSHV-HUVEC were grown in serum-free media for five days. (A) Images of
the HUVEC and KSHV-HUVEC cells were taken under bright field microscopy. Additionally
images of the KSHV-HUVEC (which express GFP) were taken under fluorescence
microscopy. Time-points included were 24, 48, 72, 96 and 120 hours post-serum starvation.
Images shown were taken at 4X magnification. (B) Graph of the percent of live cells at different
time points. The number of live cells in ten different fields were counted and averaged.
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Figure 3. KSHV infection suppresses apoptosis induced by etoposide and staurosporine
(A) HUVEC and KSHV-HUVEC were treated with endothelial media, EBM-2, containing 500
ng/ml TNFα, 100 μM etoposide or 20nM staurosporine for 24 hours. Cells were then harvested
and Caspase-3 activity was measured using the Caspase-3 substrate, DEVD-AFC. Etoposide
and staurosporine, but not TNFα, induced Caspase-3 activation in the HUVEC and KSHV-
HUVEC. However, Caspase-3 activity induced in KSHV-infected HUVEC was lower than
that induced in uninfected HUVEC. (B) HUVEC and KSHV-HUVEC were incubated in
EGM-2 media containing 10%FBS, with either 100 μM etoposide, 100 μM etoposide plus
50μM Z-VAD-FMK, 20nM staurosporine, or 20nM staurosporine plus 50μM Z-VAD-FMK
for 24 hours. Cells were then harvested and Caspase-3 activity was measured as above. Z-
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VAD-FMK, a Caspase-3 inhibitor, dramatically suppressed Caspase-3 activity induced by
etoposide and staurosporine in HUVEC and KSHV-HUVEC. (C) HUVEC and KSHV-
HUVEC were incubated in EBM-2 media, containing either 100μM etoposide or 20nM
staurosporine for 24 hours. Cells were then harvested and PARP-1 activity was measured using
a Colorimetric PARP Assay kit (Trevigen). KSHV-HUVEC treated with etoposide maintained
higher PARP-1 activity compared to uninfected HUVEC. D) HUVEC and KSHV-HUVEC
were incubated in EGM-2 media containing 10%FBS, with either 100 μM etoposide, 100 μM
etoposide plus 50μM Z-VAD-FMK, 20nM staurosporine, or 20nM staurosporine plus 50μM
Z-VAD-FMK for 24 hours. Cells were then harvested and PARP-1 activity was measured as
above. Z-VAD-FMK dramatically increased PARP-1 activity in HUVEC and KSHV-HUVEC
stimulated with etoposide and staurosporine.
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Figure 4. Tubule formation assay for HUVEC and KSHV-HUVEC
(A) HUVEC and KSHV-HUVEC were plated on growth factor reduced matrigel in the
presence of media with serum for 24 hours and allowed to form capillary-like tubules. (B)
KSHV-negative BJAB and KSHV-positive BCBL-1 cells were incubated in plain RPMI media
without serum for 48 hours at 37°C, and then the conditioned media from both cell lines were
harvested for tubule formation assays. HUVEC and KSHV-HUVEC were seeded on matrigel
to form capillary-like tubules in the presence of media without serum, or conditioned media
from BJAB or BCBL-1 cells. Images of the HUVEC and KSHV-HUVEC cells were taken
under bright field microscopy. Additionally images of the KSHV-HUVEC (which express
GFP) were taken under fluorescence microscopy. KSHV-HUVEC cells were capable of
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forming more tubules than the uninfected HUVEC under all three conditions. (C) Depicted is
the angiogenic index, which reflects the number of branch points formed under each condition.
Shown is the average number of branch points in five different fields per sample.
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Figure 5. KSHV infection of endothelial cells allows tubule formation in the absence of VEGF and
bFGF
(A) Tubule formation assays were performed with HUVEC and KSHV-HUVEC in endothelial
cell complete media, media without VEGF, or media without bFGF for four days. Images of
the HUVEC and KSHV-HUVEC cells were taken under bright field microscopy. Additionally
images of the KSHV-HUVEC (which express GFP) were taken under fluorescence
microscopy. The following time-points were taken: 24 hours (panel A), 48 hours (panel B), 72
hours (panel C), and 96 hours (panel D) hours. Images shown were taken at 10X magnification.
The tubules formed by KSHV-HUVEC appeared to be maintained on matrigel for a longer
period of time compared with those formed by HUVEC. (B) Tubule formation assays were
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performed with HUVEC and KSHV-HUVEC in serum-free EBM-2 media, with or without
anti-VEGF antibody. Images were taken after 16 hours at 4X magnification. Uninfected
HUVEC could not form tubules in the presence of the blocking VEGF antibody. Although
overall numbers of tubules was greatly reduced, KSHV-infected HUVEC could still form a
few tubules in the presence of the blocking antibody.
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Figure 6. NF-κB and PI3K pathways are essential for tubule formation by KSHV-HUVEC
(A) The tubule formation assays were performed on matrigel with HUVEC and KSHV-
HUVEC in EBM-2 media containing 50nM Rapamycin (mTOR inhibitor), 150μM Ciglitazone
(AMPK activator), 2.5μM SU6656 (Src inhibitor), 20μM Piceatannol (Syk inhibitor), 5μM
Bay11-7085 (NF-κB inhibitor) or 20μM LY294002 (PI3K inhibitor). Images of the HUVEC
and KSHV-HUVEC cells under bright field were taken at 24, 48, 72 and 96 hours. KSHV-
HUVEC were also imaged under fluorescence microscopy. Images shown were taken at 4X
magnification. (B) Depicted is the angiogenic index, which reflects the number of branch points
formed under each condition. Shown is the average number of branch points in five different
fields per sample.
Wang and Damania Page 21
Cancer Res. Author manuscript; available in PMC 2009 June 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
